Pentamidine
- TRADE NAMES: NebuPent (Astellas); Pentacarinat (Sanofi-Aventis); Pentam 300 (Astellas)
- INDICATIONS: Pneumocystis jiroveci infection, trypanosomiasis, leishmaniasis
- CLASS: Antimicrobial, Antiprotozoal
- HALF-LIFE: 9.1–13.2 hours (intramuscular); 6.5 hours (intravenous)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Adefovir, Aminoglycosides, Amiodarone, Amisulpride, Amitriptyline, Amphotericin B, Cisplatin, Droperidol, Erythromycin, Foscarnet, Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Ivabradine, Levomepromazine, Moxifloxacin, Phenothiazines, Saquinavir, Sparfloxacin, Sulpiride, Tricyclic antidepressants, Trifluoperazine, Vancomycin
PREGNANCY CATEGORY: C
The rate of adverse side effects is increased in patients with AIDS.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
